Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 234,265,285 papers from all fields of science
Search
Sign In
Create Free Account
Action Code - No change
Known as:
No change
National Institutes of Health
Create Alert
Alert
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
Gemcitabine plus carboplatin used as induction regimen for elderly patients with locally advanced unresectable non-small cell lung cancer
Zhihua Sun
,
Hong Zheng
,
Linyun Zhang
2011
Corpus ID: 72865814
ObjectiveThe purpose of this study was to evaluate the efficacy and safety of gemcitabine (GEM) and carboplatin (CBP) used as…
Expand
2004
2004
A phase II study of m-AMSA in patients with primary liver cancer
G. Falkson
,
B. Coetzer
,
D. Klaassen
Cancer Chemotherapy and Pharmacology
2004
Corpus ID: 19612766
SummaryThirty-five evaluable patients with histologically confirmed primary liver cancer (PLC) were treated with m-AMSA. All…
Expand
1995
1995
Second-line treatment with high-dose 5-fluorouracil and folinic acid in advanced colorectal cancer refractory to standard-dose 5-fluorouracil treatment.
E. Jäger
,
O. Klein
,
B. Wächter
,
B. Müller
,
U. Braun
,
A. Knuth
Oncology
1995
Corpus ID: 46859512
Results with second-line treatment of advanced colorectal cancer are poor. Preliminary phase I/II results suggest encouraging…
Expand
1995
1995
Benefits of medroxyprogesterone acetate (MPA) in advanced or recurrent breast cancer with higher serum concentration
R. Nishimura
,
K. Nagao
,
+6 authors
Takahito Saiki
Breast Cancer
1995
Corpus ID: 23919291
The efficacy of medroxyprogesterone acetate (MPA) therapy in controlling progressive measurable metastatic breast cancer was…
Expand
1992
1992
[Combination therapy with natural type human tumor necrosis factor (MHR-24) and human lymphoblastoid interferon-alpha (MOR-22) against renal cell carcinoma--a multiclinic cooperative, early phase II…
T. Niijima
,
H. Akaza
,
+7 authors
K. Koiso
Hinyokika kiyo. Acta urologica Japonica
1992
Corpus ID: 40989873
The combination therapy with natural type human tumor necrosis factor (n-TNF; MHR-24) and human lymphoblastoid interferon-alpha…
Expand
1990
1990
Treatment of disseminated malignant melanoma with cisplatin in combination with whole-body hyperthermia and doxorubicin.
R. Engelhardt
,
U. Müller
,
R. Weth-Simon
,
H. Neumann
,
Löhr Gw
International Journal of Hyperthermia
1990
Corpus ID: 56486
Twenty-three patients with disseminated malignant melanoma were entered in a pilot study conducted from January 1983 to January…
Expand
Review
1990
Review
1990
Initial Results of Phase I/II Interstitial Thermoradiotherapy for Primary Advanced and Local Recurrent Tumors
P. Phromratanapongsc
,
M. Seegenschmiedt
,
+4 authors
R. Fietkau
American Journal of Clinical Oncology
1990
Corpus ID: 28018845
Since January 1986 in a phase I/II study. 45 lesions (30 head and neek, 11 pelvie, and 4 other lesions) in 44 patients (24 men…
Expand
1987
1987
5-Fluorouracil, 4-epidoxorubicin, and mitomycin C (FEM) combination chemotherapy for advanced gastric carcinoma. A phase-II trial by the "chemotherapiegruppe gastrointestinaler tumoren (CGT)".
H. Flechtner
,
W. Queisser
,
+7 authors
F. Trux
Onkologie
1987
Corpus ID: 46816464
In a phase-II-trial 40 patients with advanced gastric cancer were treated with 5-fluorouracil, 4-epidoxorubicin, mitomycin C (FEM…
Expand
1987
1987
Rezidivhäufigkeit und Langzeit-Überleben beim kleinzelligen Bronchialkarzinom
M. Wolf
,
K. Havemann
,
R. Holle
,
P. Drings
,
K. Hans
,
M. Schroêder
1987
Corpus ID: 57586605
Analyses of relapse in small cell lung cancer (SCLC) were performed in 443 evaluable patients included in two multicenter trials…
Expand
1983
1983
[Intra-arterial infusion through 2 routes in liver (primary and metastatic cancer].
F. Koba
,
H. Tsuii
,
+9 authors
T. Baba
Gan to kagaku ryoho. Cancer & chemotherapy
1983
Corpus ID: 43564766
Patients with unresectable liver cancer (primary and metastatic) were treated with a newly-devised arterial infusion chemotherapy…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE